Table 5.
Roles of miRNAs in metastasis signature. Log2 fold change and adjusted p-value refer to the comparison of metastatic against primary CM samples.
| miRNA | log2 Fold Change | Adjusted p Value | Role in the Literature |
|---|---|---|---|
| mir-186 | 0.290805 | 0.000389 | Regulates TGFβ by suppressing SMAD6-7 in colorectal cancer and inhibits cell proliferation in melanoma [85,86]. |
| mir-671 | −0.24244 | 0.027927 | miR-671-5p reduces NSCLC (squamous carcinoma) metastasis [87]. Its upregulation slows down proliferation and metastasis of A375 melanoma cells [88]. |
| mir-760 | 0.503684 | 0.012509 | It has been found downregulated in several cancers that can act both as tumor suppressor and as oncomir [89]. |
| mir-944 | −3.41097 | 8.62 × 10−37 | Suppresses EMT in colorectal cancer [90]. It has been reported as downregulated in hepatocellular carcinoma (HCC) and suppresses the malignancy of HCC by deactivating PI3K [91]. Its overexpression is correlated with poor prognosis in cervical cancer [92]. |
| mir-1976 | 0.444564 | 0.000327 | It has been identified as tumor suppressor in NSCLC [93]. Its downregulation has been correlated with worse overall survival in triple-negative breast cancer (TNBC) from TCGA [94]. |
| mir-3610 | 0.339103 | 0.049814 | It has been associated with sumoylation, a molecular signature in head and neck cancer [95]. |
| mir-3615 | 0.245396 | 0.036379 | Its upregulation is correlated with high TNM stage and high proliferation in HCC [96]. |
| mir-6842 | 0.450524 | 0.003272 | N/A |